Comparing two drug combinations for moderate-to-severe pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study compares two treatments for moderate-to-severe pemphigus vulgaris, a rare skin blistering condition. One group gets rituximab plus corticosteroids, the other gets corticosteroids plus azathioprine. It aims to find which combination works better to control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have active moderate-to-severe pemphigus vulgaris, either newly diagnosed or a flare-up of your disease.
- Your diagnosis was confirmed with a skin biopsy and direct immunofluorescence.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
- You do not have a serious infection, active cancer, or severe heart, kidney, or liver disease.
- You have not had rituximab treatment in the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
This study is for adults with certain autoimmune blistering skin conditions. Researchers want to better understand and test treatments that could improve symptoms and healing for people with these specific diseases.
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
Hear when a new Pemphigus Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.